Angioline Group is the largest Russian developer and manufacturer of medical devices for interventional cardiology since 2009, based in Novosibirsk. Today the company's portfolio includes more than 20 types of medical devices for endovascular interventions on coronary arteries: coronary stents "Calypso" and "Sinus", balloon, conductive and diagnostic catheters, consumables for angiography and angioplasty, coronary conductors. He is a permanent research partner and clinical base for the majority of Angioline's developments, the leading cardiovascular clinic in Russia, and the Academician Meshalkin Research Center of the Ministry of Health of the Russian Federation. New serious developments of Angioline Group of Companies - aortic valve of heart, cava-filter, stent graft, ULP occluder - are at the stage of registration and production. This production has no domestic analogues and successfully solves problems of import substitution and health of the nation.
The quality management system of the company is certified according to the requirements of the new international standard ISO 13485:2016 & EN ISO 13485:2016, the scope of the certificate is extended - endocardial products, surgical suture material with needles are added. In 2019, construction of the second production facility in the Novosibirsk Region is being completed. Angioline Trading Ltd. is also part of the Group's structure.
To date, more than 150,000 implantations of Angioline products have been performed.
The company's medical products are used by 220 largest clinics in 63 regions.
Every hour about five Angioline stents are implanted in Russian hospitals.